United-Guardian, Inc. (UG) Income Statement Analysis

See more : Ajinomoto Co., Inc. (2802.T) Income Statement Analysis – Financial Results

Complete financial analysis of United-Guardian, Inc. (UG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of United-Guardian, Inc., a leading company in the Household & Personal Products industry within the Consumer Defensive sector.

You may be interested

United-Guardian, Inc. (UG)

Industry: Household & Personal Products

Sector: Consumer Defensive

Website: https://www.u-g.com

About United-Guardian, Inc.

United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and proprietary specialty industrial products in the United States and internationally. The company offers cosmetic ingredients, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL NATURAL consisting of natural ingredients for cosmetic use; LUBRAJEL MARINE; LUBRASIL II SB, a special formulation of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base; LUBRAJEL II XD; B-122, a powdered lubricant that is used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; KLENSOFT, a surfactant, which is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. Its medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL LC and LUBRAJEL FA that are LUBRAJEL formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. The company's pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial product to treat infections in the urinary bladder, and localized infections in the peritoneum, as well as eye, ear, nose and throat, and sinuses. Its industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. The company also conducts research and development primarily related to the development of cosmetic ingredients. It markets its products through marketing partners, distributors, and wholesalers. The company was founded in 1942 and is based in Hauppauge, New York.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986
Revenue	10.89M	12.70M	13.93M	10.99M	13.60M	13.77M	12.97M	10.78M	14.01M	13.45M	15.42M	13.83M	14.34M	13.72M	13.28M	12.29M	11.89M	12.20M	12.13M	11.12M	11.16M	9.09M	9.58M	10.45M	9.10M	8.80M	8.80M	8.00M	7.00M	6.70M	7.00M	6.30M	5.00M	4.60M	7.10M	6.10M	4.80M	4.50M
Cost of Revenue	5.48M	6.00M	5.75M	4.87M	5.66M	5.67M	5.30M	4.88M	5.20M	5.32M	5.61M	5.22M	5.65M	5.25M	5.32M	5.41M	4.85M	5.64M	5.69M	5.07M	5.06M	4.90M	4.65M	4.76M	4.60M	4.40M	5.00M	4.90M	4.20M	4.20M	4.10M	3.60M	3.00M	4.40M	6.70M	4.40M	3.40M	2.80M
Gross Profit	5.41M	6.70M	8.18M	6.11M	7.94M	8.10M	7.67M	5.89M	8.80M	8.13M	9.81M	8.61M	8.69M	8.47M	7.95M	6.88M	7.03M	6.55M	6.44M	6.05M	6.10M	4.19M	4.93M	5.68M	4.50M	4.40M	3.80M	3.10M	2.80M	2.50M	2.90M	2.70M	2.00M	200.00K	400.00K	1.70M	1.40M	1.70M
Gross Profit Ratio	49.66%	52.78%	58.74%	55.65%	58.40%	58.84%	59.12%	54.69%	62.86%	60.46%	63.61%	62.25%	60.59%	61.74%	59.90%	55.98%	59.17%	53.74%	53.10%	54.40%	54.64%	46.14%	51.44%	54.41%	49.45%	50.00%	43.18%	38.75%	40.00%	37.31%	41.43%	42.86%	40.00%	4.35%	5.63%	27.87%	29.17%	37.78%
Research & Development	463.99K	490.77K	478.64K	451.21K	397.39K	399.52K	646.08K	651.83K	648.21K	730.41K	717.00K	693.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	1.79M	1.85M	1.86M	2.64M	2.50M	2.51M	2.55M	3.42M	2.61M	2.70M	2.60M	2.83M	2.59M	2.59M	2.46M	2.30M	2.34M	2.26M	2.10M	2.20M	2.00M	2.00M	1.90M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	2.08M	2.17M	2.04M	2.03M	2.15M	2.12M	1.79M	1.85M	1.86M	2.64M	2.50M	2.51M	2.55M	3.42M	2.61M	2.70M	2.60M	2.83M	2.59M	2.59M	2.46M	2.30M	2.34M	2.26M	2.10M	2.20M	2.00M	2.00M	1.90M	1.80M	1.80M	1.80M	1.30M	100.00K	0.00	1.70M	1.80M	1.50M
Other Expenses	0.00	2.17M	2.04M	2.03M	2.15M	2.12M	1.14M	1.20M	1.21M	24.40K	1.07M	518.05K	2.55M	2.57M	2.61M	2.70M	2.60M	0.00	0.00	0.00	0.00	0.00	0.00	295.27K	300.00K	600.00K	400.00K	300.00K	300.00K	200.00K	200.00K	200.00K	100.00K	200.00K	200.00K	0.00	0.00	200.00K
Operating Expenses	2.54M	2.66M	2.51M	2.48M	2.55M	2.52M	2.43M	2.50M	2.51M	2.64M	2.50M	2.51M	2.55M	3.42M	2.61M	2.70M	2.60M	2.83M	2.59M	2.59M	2.46M	2.30M	2.34M	2.56M	2.40M	2.80M	2.40M	2.30M	2.20M	2.00M	2.00M	2.00M	1.40M	300.00K	200.00K	1.70M	1.80M	1.70M
Cost & Expenses	8.02M	8.66M	8.26M	7.35M	8.20M	8.19M	7.73M	7.39M	7.71M	7.96M	8.12M	7.73M	8.20M	8.67M	7.93M	8.11M	7.45M	8.47M	8.28M	7.66M	7.52M	7.20M	6.99M	7.32M	7.00M	7.20M	7.40M	7.20M	6.40M	6.20M	6.10M	5.60M	4.40M	4.70M	6.90M	6.10M	5.20M	4.50M
Interest Income	306.65K	236.70K	233.86K	226.25K	203.33K	0.00	0.00	0.00	0.00	0.00	0.00	325.02K	332.65K	455.79K	395.26K	492.44K	575.03K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	1.62M	0.00	0.00	0.00	227.98K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	56.00	798.00	0.00	0.00	0.00	0.00	38.00	536.00	0.00	0.00	100.00K	100.00K	100.00K	100.00K	100.00K	100.00K	200.00K	200.00K	300.00K	200.00K	100.00K	200.00K
Depreciation & Amortization	105.68K	135.40K	145.98K	165.26K	175.81K	191.94K	200.68K	187.04K	173.48K	181.19K	189.73K	254.44K	255.58K	229.78K	178.69K	200.80K	197.80K	195.37K	205.81K	209.79K	203.81K	256.99K	275.30K	295.27K	300.00K	600.00K	400.00K	300.00K	300.00K	200.00K	200.00K	200.00K	100.00K	200.00K	200.00K	0.00	-100.00K	200.00K
EBITDA	2.97M	4.17M	5.81M	3.80M	5.57M	5.77M	5.44M	3.58M	6.47M	5.67M	6.16M	6.35M	6.39M	5.29M	5.52M	4.38M	4.64M	3.86M	4.06M	3.67M	3.85M	2.15M	2.87M	3.42M	2.40M	2.10M	1.80M	1.10M	900.00K	700.00K	1.10M	900.00K	700.00K	300.00K	100.00K	-200.00K	-400.00K	-400.00K
EBITDA Ratio	27.27%	38.17%	39.17%	28.32%	35.01%	41.35%	37.94%	30.34%	43.80%	38.86%	39.96%	38.12%	41.76%	38.53%	41.59%	35.72%	38.92%	28.75%	31.48%	31.03%	32.95%	21.52%	27.43%	30.50%	25.27%	23.86%	20.45%	12.50%	12.86%	10.45%	15.71%	12.70%	12.00%	-4.35%	5.63%	-3.28%	-10.42%	11.11%
Operating Income	2.86M	4.04M	5.67M	3.64M	5.40M	5.58M	5.24M	3.39M	6.29M	5.49M	7.30M	6.10M	6.14M	5.06M	5.34M	4.18M	4.44M	3.72M	3.85M	3.46M	3.64M	1.89M	2.59M	3.13M	2.10M	1.60M	1.40M	800.00K	600.00K	500.00K	900.00K	700.00K	600.00K	-100.00K	200.00K	-200.00K	-400.00K	300.00K
Operating Income Ratio	26.30%	31.79%	40.68%	33.10%	39.68%	40.52%	40.37%	31.45%	44.93%	40.83%	47.36%	44.11%	42.79%	36.86%	40.25%	34.02%	37.33%	30.54%	31.74%	31.13%	32.64%	20.81%	27.06%	29.95%	23.08%	18.18%	15.91%	10.00%	8.57%	7.46%	12.86%	11.11%	12.00%	-2.17%	2.82%	-3.28%	-8.33%	6.67%
Total Other Income/Expenses	387.75K	-809.55K	210.84K	524.83K	634.41K	-113.99K	315.17K	306.51K	331.83K	264.00K	1.33M	828.21K	736.09K	455.79K	395.68K	484.68K	583.93K	470.11K	237.46K	220.99K	169.34K	192.10K	239.08K	237.61K	100.00K	0.00	-100.00K	0.00	-100.00K	-300.00K	-200.00K	-100.00K	-100.00K	100.00K	100.00K	200.00K	-100.00K	-100.00K
Income Before Tax	3.25M	3.23M	5.88M	4.16M	6.03M	5.47M	5.55M	3.70M	6.63M	5.75M	8.63M	6.93M	6.87M	5.51M	5.74M	4.67M	5.02M	4.14M	4.09M	3.68M	3.81M	2.08M	2.83M	3.37M	2.20M	1.60M	1.30M	800.00K	500.00K	200.00K	700.00K	600.00K	500.00K	0.00	300.00K	0.00	-500.00K	500.00K
Income Before Tax Ratio	29.86%	25.42%	42.20%	37.88%	44.34%	39.70%	42.80%	34.30%	47.30%	42.79%	55.99%	50.10%	47.92%	40.18%	43.23%	37.97%	42.25%	33.92%	33.70%	33.11%	34.16%	22.92%	29.55%	32.22%	24.18%	18.18%	14.77%	10.00%	7.14%	2.99%	10.00%	9.52%	10.00%	0.00%	4.23%	0.00%	-10.42%	11.11%
Income Tax Expense	669.41K	658.17K	1.22M	856.02K	1.27M	1.11M	1.71M	1.11M	2.02M	1.70M	2.73M	2.10M	2.16M	1.71M	1.86M	1.50M	1.60M	1.40M	1.47M	1.21M	1.34M	662.34K	941.06K	1.31M	800.00K	600.00K	500.00K	300.00K	200.00K	100.00K	200.00K	200.00K	200.00K	500.00K	300.00K	-200.00K	-100.00K	200.00K
Net Income	2.58M	2.57M	4.66M	3.30M	4.76M	4.35M	3.84M	2.58M	4.61M	4.05M	5.90M	4.83M	4.72M	3.80M	3.88M	3.16M	3.54M	2.74M	2.62M	2.48M	2.47M	1.42M	1.89M	2.05M	1.40M	1.00M	800.00K	500.00K	300.00K	100.00K	500.00K	600.00K	300.00K	-600.00K	0.00	-200.00K	-400.00K	100.00K
Net Income Ratio	23.71%	20.23%	33.44%	30.08%	35.01%	31.61%	29.64%	23.95%	32.89%	30.12%	38.29%	34.94%	32.89%	27.69%	29.22%	25.73%	29.81%	22.44%	21.57%	22.25%	22.15%	15.64%	19.73%	19.65%	15.38%	11.36%	9.09%	6.25%	4.29%	1.49%	7.14%	9.52%	6.00%	-13.04%	0.00%	-3.28%	-8.33%	2.22%
EPS	0.56	0.56	1.01	0.72	1.04	0.95	0.84	0.56	1.00	0.88	1.28	1.05	1.03	0.80	0.78	0.64	0.72	0.55	0.53	0.50	0.50	0.29	0.39	0.42	0.28	0.21	0.17	0.11	0.06	0.03	0.10	0.12	0.06	-0.12	0.00	-0.05	-0.07	0.02
EPS Diluted	0.56	0.56	1.01	0.72	1.04	0.95	0.84	0.56	1.00	0.88	1.28	1.05	1.03	0.80	0.78	0.64	0.72	0.55	0.53	0.50	0.50	0.29	0.39	0.42	0.28	0.21	0.17	0.11	0.06	0.03	0.10	0.12	0.06	-0.12	0.00	-0.05	-0.07	0.02
Weighted Avg Shares Out	4.59M	4.59M	4.59M	4.59M	4.59M	4.58M	4.59M	4.59M	4.59M	4.60M	4.60M	4.60M	4.60M	4.74M	4.95M	4.95M	4.94M	4.94M	4.94M	4.93M	4.90M	4.88M	4.87M	4.88M	4.89M	4.88M	4.71M	4.55M	5.00M	5.00M	5.00M	5.00M	5.00M	5.00M	4.76M	4.00M	5.71M	4.80M
Weighted Avg Shares Out (Dil)	4.59M	4.59M	4.59M	4.59M	4.59M	4.58M	4.59M	4.59M	4.59M	4.60M	4.60M	4.60M	4.60M	4.74M	4.95M	4.95M	4.95M	4.94M	4.94M	4.94M	4.91M	4.89M	4.89M	4.91M	4.91M	4.90M	4.71M	4.55M	5.00M	5.00M	5.00M	5.00M	5.00M	5.00M	4.76M	4.00M	5.71M	4.80M

United-Guardian Reports Y/Y Rise in Q3 Earnings, Flat Revenues

November 12, 2024zacks.com

UG's Q3 earnings gain from effective cost management and increased demand for its cosmetic ingredients segment.

United-Guardian Reports Increased Third Quarter Earnings

November 8, 2024globenewswire.com

HAUPPAUGE, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and the first nine months of 2024. Sales for the nine-month period ended September 30th increased from $8,278,141 in 2023...

Gold Rises on Possible Technical Recovery

October 23, 2024wsj.com

Gold rose in the early morning Asian session on a possible technical recovery.

Greatland Gold rises as Newmount makes progress on conditions for deal

September 26, 2024proactiveinvestors.co.uk

Greatland Gold PLC (AIM:GGP, OTC:GRLGF) shares rose almost 5% after it said "significant progress" has been made on two of the conditions needed to complete its acquisition from Newmont Corporation (NYSE:NEM, TSX:NGT, ASX:NEM). Two weeks ago the AIM-listed company struck a US$475 million deal...

Gold rises as crude struggles: China slowdown and global shifts - Mike McGlone

September 24, 2024kitco.com

Jeremy Szafron joins Kitco News as an anchor and producer from Kitco's Vancouver bureau. Jeremy is a seasoned journalist with a diverse background covering entertainment, current affairs and finance.

United-Guardian (UG) Posts Y/Y Q2 Earnings & Sales Growth

August 13, 2024zacks.com

Higher cosmetic ingredient sales aid United-Guardian's (UG) earnings in Q2.

United-Guardian Reports Increased Second Quarter Sales & Earnings

August 9, 2024globenewswire.com

HAUPPAUGE, N.Y., Aug. 09, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2024. Sales for the six-month period ended June 30th increased from $5,220,623 in 2023 to $6,645,149...

Wall Street Set To Tumble As Macro Concerns Return, VIX Spikes And Global Markets Sell Off: Safe-Haven Gold Rises To Record High As Traders Eye July Jobs Data

August 2, 2024benzinga.com

U.S. stocks were priming for more losses on Friday as traders await the key non-farm payrolls report. Tech stocks could again take the brunt of the selling amid some sector-specific concerns and the ongoing rotation out of the sector.

United-Guardian Announces Dividend Increase

July 12, 2024globenewswire.com

HAUPPAUGE, N.Y., July 12, 2024 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today that the company's Board of Directors, at its meeting on July 10, 2024, declared a cash dividend of $0.35 per share, to be paid on July 31,...